By Robb M. Stewart
Acasti Pharma said Wednesday it has aligned with the U.S. Food and Drug Administration on the protocol for its late-stage trial of its lead clinical asset, GTX-104.
The Quebec-based biopharmaceutical company also said it has received guidance from the regulator on a potential new drug application package for a novel injectable…
Read the full article here
